Evidence map›Paper›PMID 33728461›Full record

ArticleTransactions of the Royal Society of Tropical Medicine and Hygiene2021

Corrigendum to: Medicine donation programmes supporting the global drive to end the burden of neglected tropical diseases.

Mark Bradley, Rachel Taylor, Julie Jacobson, Morgane Guex, Adrian Hopkins, Julie Jensen, Lynn Leonard, Johannes Waltz, Luc Kuykens, Papa Salif Sow and 9 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Mark BradleyGlobal Health, GSK, Brentford, UK.
Rachel TaylorCorporate Responsibility, Merck & Co., Inc., Kenilworth, NJ, USA.
Julie JacobsonBridges to Development, Seattle, Washington, USA.
Morgane GuexInternational Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland.
Adrian HopkinsAdrian Hopkins Consulting, Gravesend, Kent, UK.
Julie JensenGlobal Health & Patient Access, Pfizer, Inc. New York, NY, USA.
Lynn LeonardJohnson & Johnson Global Public Health, New Brunswick, NJ, USA.
Johannes WaltzGlobal Health, Group Corporate Affairs Merck KGaA, Darmstadt, Germany.
Luc KuykensGlobal Health Programs, Sanofi, Paris, France.
Papa Salif SowGlobal Patient Solutions Africa, Gilead Sciences, Foster City, CA, USA.
Ulrich-Dietmar MadejaNeglected Tropical Disease Programs, Bayer AG Pharmaceuticals, Berlin, Germany.
Takayuki HidalSustainability, Eisai Co. Ltd, Tokyo, Japan.
Kileken Ole-MoiyoiNovartis Global Health & Corporate Responsibility, Basel, Switzerland.
Jonathan KingDepartment of Control of Neglected Tropical Diseases, WHO Geneva, Geneva, Switzerland.
Daniel ArgawDepartment of Control of Neglected Tropical Diseases, WHO Geneva, Geneva, Switzerland.
Jamsheed MohamedDepartment of Communicable Diseases WHO Regional Office for South-East Asia, Delhi, India.
Maria Rebollo PoloExpanded Special Project for Elimination of NTDs (ESPEN) WHO Regional Office for Africa, Brazzaville, Congo.
Aya YajimaDivision of Programs for Disease Control WHO Regional Office for the Western Pacific, Manila, Philippines.
Eric OttesenNTD Support Centre, Task Force for Global Health Atlanta, USA.

Funding

World Health Organization 001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33728461
PMCPMC8106903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.